CCR2 and glioma: In glioma-bearing mice, the combination of purified CCR2+HSCs + PD-1 led to significantly increased median survival and long-term survivors over the PD-1 alone group (p = 0.0006), as well as the cohort that received bulk HSCs + PD-1 (p = 0.0233)(Fig. 8b).